GerdCare Medical

First-Ever Noninvasive and Drug Free Technology to Treat Gastroesophageal Reflux Disease (GERD)

Health Tech & Life Sciences

Private

Company Overview

Snapshot

Founded in September 2017 by Shimon Eckhouse, Moti Esh, and Giora Arbel, GerdCare Medical operates with 1–10 employees. The company has completed 2 funding rounds with 1 investor. In April 2025, GerdCare Medical secured a follow-on investment from Alon MedTech Ventures.

Business overview

GerdCare Medical is pioneering a non-invasive, drug-free technology to treat Gastroesophageal Reflux Disease (GERD). The company's solution includes a smart wearable device that delivers targeted electrical stimulation, a proprietary mobile app for personalized treatment optimization and tracking, and a secure clinician dashboard for remote patient monitoring. GerdCare Medical aims to address the unmet clinical needs of over 1 billion people affected by GERD globally, particularly those unresponsive to existing drug therapies. The company serves the global healthcare market, focusing on medical devices and medical treatment & therapeutics within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is GerdCare Medical's core technology?: GerdCare Medical has developed a wearable, drug-free, non-invasive GERD treatment that uses targeted electrical stimulation to restore the function of the gastroesophageal barrier. This is complemented by a mobile app for treatment optimization and a clinician dashboard for remote monitoring.
When was GerdCare Medical founded and by whom?: GerdCare Medical was founded in September 2017 by Shimon Eckhouse, Moti Esh, and Giora Arbel.
Which investor participated in GerdCare Medical's funding rounds?: Alon MedTech Ventures has invested in GerdCare Medical, with a follow-on investment in April 2025 and an initial investment in January 2018.
What is the current product stage of GerdCare Medical's solution?: GerdCare Medical's product is currently in the Clinical Trial stage, with a pivotal, FDA-approved clinical trial actively enrolling patients.
What markets does GerdCare Medical target?: GerdCare Medical targets the global market, with a focus on the United States and Europe, addressing the needs of patients and healthcare providers.

External links

GerdCare Medical — full profile (machine-readable)

GerdCare Medical Ltd, a company pioneering a new era in the global treatment of Gastroesophageal Reflux Disease (GERD). With over 1 billion people affected worldwide—and up to 40% unresponsive to existing drug therapies — GERD remains a critical and underserved health challenge. Current treatments, such as proton pump inhibitors (PPIs) and surgery, either mask symptoms without addressing the underlying cause or involve significant risks and low patient uptake. GerdCare is addressing this unmet clinical need. Our Breakthrough Solution GerdCare has developed the first-ever wearable, drug-free, non-invasive GERD treatment designed to restore the function of the gastroesophageal barrier—directly targeting the root cause of GERD, not just its symptoms. Our solution includes: • A smart wearable device delivering targeted electrical stimulation • A proprietary mobile app for personalized treatment optimization and tracking • A secure clinician dashboard enabling remote patient monitoring Clinically Validated Outcomes • Rapid symptom relief by significant reduction / normalization of esophageal acidity and GERD symptoms (such as heartburn and regurgitation) within 3–4 days • Up to 75% reduction in regurgitation, compared to approximately 10% - 15% with standard drug therapy • Excellent safety profile across proof-of-concept and pilot studies • Pivotal, FDA-approved clinical trial currently enrolling patients Market Opportunity • $6.3B+ global GERD therapeutics market, growing at 3.6% CAGR • 23M refractory patients in the US and EU alone • Razor-and-blade model with recurring consumables revenue • 80% gross margins and strong potential for both medical devices and pharma partnerships GerdCare holds multiple issued patents in the US, EU, Asia, IL.

Facts
Name	GerdCare Medical
One-liner	First-Ever Noninvasive and Drug Free Technology to Treat Gastroesophageal Reflux Disease (GERD)
Type	Startup
Primary sector	Health Tech & Life Sciences
Founded	2017
Employees	1-10
Employees (exact)	2
HQ / location	Yokne'am Illit, HaTnufa St 3, Yokne'am Illit, Israel, North District
Product stage	Clinical Trial
Website	https://www.gerd-care.com/
LinkedIn	https://www.linkedin.com/company/69738892
IL Registrar	515722551

Facts

Name

GerdCare Medical

One-liner

First-Ever Noninvasive and Drug Free Technology to Treat Gastroesophageal Reflux Disease (GERD)

Type

Startup

Primary sector

Health Tech & Life Sciences

Founded

2017

Employees

1-10

Employees (exact)

HQ / location

Yokne'am Illit, HaTnufa St 3, Yokne'am Illit, Israel, North District

Product stage

Clinical Trial

Website

https://www.gerd-care.com/

https://www.linkedin.com/company/69738892

IL Registrar

515722551

Classification
Sectors	Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics
Core technology	Platforms & Interfaces, Mobile
Target customers	Healthcare & Life Sciences, Healthcare, Patients, Providers
Business models	B2B2C, B2C
Tags	non-invasive, wearable, treatments, medical-devices, gastroenterology, chronic-disease

Classification

Sectors

Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics

Core technology

Platforms & Interfaces, Mobile

Target customers

Healthcare & Life Sciences, Healthcare, Patients, Providers

Business models

B2B2C, B2C

Date	Round	Amount	Investors
Jan 2018	Seed	Undisclosed	Alon MedTech Ventures
Apr 2025	A Round	Undisclosed	Alon MedTech Ventures

Name	Role	Founder
Shimon Eckhouse	Chairman	yes
David Hanuka	CEO
Moti Esh	Co-founder & CTO	yes
Giora Arbel	Co-founder & VP R&D	yes

GerdCare Medical

Company Overview

Snapshot

Business overview

Company Intelligence Q&A

External links

Generate Slim Page